Wolverine Trading’s BioLineRX BLRX Stock Holding History

Wolverine Trading’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-19	Closed	-$13K	–	4441
2016 Q3	$13K	Buy	+19	New	+$10.1K	﹤0.01%	4525

Other funds holding BLRX

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Wolverine Trading's BLRX Position: Q4 2016 in Review

Wolverine Trading sold out of BioLineRX (BLRX) in Q4 2016, closing a stake of 19 shares — an estimated $13K sold.

Wolverine Trading first reported a position in BLRX in Q3 2016 and held it in 1 quarter. The position peaked at $13K in Q3 2016. 22 funds tracked by Wall St. Rank hold BLRX as of Q4 2016.

Wolverine Trading reported no remaining BioLineRX position as of Q4 2016 after selling out during the quarter.
Wolverine Trading sold 19 BioLineRX shares in Q4 2016, an estimated $13K.
Wolverine Trading first reported a position in BioLineRX in Q3 2016 and held it in 1 quarter.
Wolverine Trading's BioLineRX position peaked at $13K in Q3 2016.
22 funds tracked by Wall St. Rank held BioLineRX as of Q4 2016.

Based on Wolverine Trading's 13F filing for Q4 2016, filed 14 Feb 2017.